ST. PAUL, Minn., April 11, 2012 /PRNewswire/ -- Gamma Pharmaceuticals, Inc. (PINKSHEETS: GMPM.PK) a marketing and product formulation company focused on alternative delivery systems for everyday health and wellness, announced this afternoon, the signing of a Distribution Agreement with Purchase Order for the Company's 17-gram Gamma Energy GEL. The initial order is for approximately $70,000 retail value. Gamma will support sales with point of purchase materials and social media. Gamma is also in discussions with groups to support street level marketing and product sampling. The Company views sampling as the most effective marketing tool to convey Gamma Energy GEL's superior texture and taste: "if you try it you will buy it."
This Distribution Agreement represents an important piece in Gamma's overall distribution plan for the current fiscal year. The non-exclusive Agreement is for a one-year period and covers the New York Tri-state area. Gamma is seeking to increase overall sales in the region and to support Gamma's current sales in New York through Duane Reade Pharmacy. Gamma views New York as a lynchpin in the Company's efforts to penetrate and to gain market share nationally. The energy beverage / energy shot market are very popular with consumers in the Tri-state area. Gamma's Energy GEL is the first energy gel product to go mainstream with consumers. Management believes the energy drink market will continue to decline as consumers move to energy shots, and to Gamma's Energy GELs.
Gamma Energy GEL utilizes Gamma's proprietary GEL Delivery Technology™ to formulate and deliver a more convenient and better tasting product than competitors' 2oz. shots. Gamma's "Grab and Go" Gel Pouch fits in any pocket or purse. Gamma Energy GEL delivers the equivalent of an energy drink in each pouch. Gamma Energy GEL is formulated with natural biopolymers, for optimal benefit, including the fastest absorption of payload ingredients.
About Gamma Pharmaceuticals, Inc.
Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company focused on alternative delivery systems for everyday health and wellness. Gamma sells its own branded products through wholesalers and direct to retailers, both in the US and internationally. Gamma's core focus is the marketing and sale of vitamins and nutraceuticals, OTC pharmaceutical products and personal care products in the United States. Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action, "You've made a brilliant choice for your nutrition;" SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On." Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market. A series of innovative marketing programs support Gamma's product sales and retail partners.
At present Gamma manufactures in North America and distributes in the United States and Mexico. Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms that give consumers a more pleasant experience. Gel Delivery Technology® characteristics include rapid absorption, superior texture, convenience and great taste. Market categories Gamma targets are growing as rapidly as 60% per year. Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well-being, Menopause Symptoms and Personal Care Products. Gamma also develops and manufactures house brands for major retailers. At this time, Gamma has a total of 36 SKUs and holds licenses for 9 SKUs in China.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: Gamma Pharmaceuticals, Inc.
Joe Cunningham, President ([email protected])
Direct: (651) 204 2048
SOURCE Gamma Pharmaceuticals, Inc.